Big technology stocks like Tesla, Amazon and Microsoft just finished their worst quarter in years

Big technology stocks like Tesla, Amazon and Microsoft just finished their worst quarter in years


Elon Musk attends The 2022 Met Gala Celebrating “In America: An Anthology of Fashion” at The Metropolitan Museum of Art on May 2, 2022 in New York City. (Photo by Gotham/Getty Images)

Gotham | Getty Images

Investors lowered the valuations of the world’s largest technology companies in the second quarter as central bankers ratcheted up interest rates to ward off inflation.

Big technology names became less valuable in the first quarter, with Russia’s invasion into Ukraine cutting into business and adding to supply complications that appeared in the pandemic, sending the broad S&P 500 index down about 5%. The situation worsened in the second quarter as the Federal Reserve swung into action with rate increases. While the S&P tumbled another 16%, the technology-heavy Nasdaq Composite index declined 22%.

U.S. stocks fell Thursday to end the second quarter, prompting the S&P 500’s weakest first half of the year since 1970.

Electric vehicle maker Tesla endured its largest quarterly decline since its 2010 initial public offering as the stock sank almost 38%. In the quarter CEO Elon Musk made a bid to acquire social-media company Twitter for $44 billion.

Amazon stock dropped almost 35%, the most since the third quarter of 2001. The company’s first-quarter earnings fell short of analysts’ estimates in April as revenue growth slowed. In early June, Amazon said Dave Clark, CEO of the e-commerce company’s worldwide consumer business, was resigning. In September he will start as CEO of supply chain software start-up Flexport.

Shares of Google’s umbrella company, Alphabet, ended the quarter down almost 22%, the worst results since the fourth quarter of 2008. Microsoft shares dropped about 17%, the sharpest decline since the second quarter of 2010.

Apple’s stock fell almost 22% in the second quarter in the stock’s worst performance since the fourth quarter of 2018, when Apple reported light guidance and the stock market overall endured a steep selloff.

Facebook parent Meta Platforms — whose ticker symbol changed to META from FB this month to match its new corporate identity reflecting a stronger emphasis on virtual worlds where people can transact and interact — saw its stock fall more than 27%. That was a better outcome than the first quarter, when the stock’s value compressed by about 34%. In February the social-network operator said its count of daily active users (DAUs) on Facebook had decreased quarter-over-quarter for the first time.

Drugmakers Eli Lilly and Merck, cereal manufacturer Kellogg and discount retailer Dollar General all outperformed these six companies, posting gains of at least 10% in the quarter.

WATCH: A lot of names will never recover in growth tech, says EMJ Capital’s Eric Jackson



Source

Why XRP ETFs are seeing steady inflows despite crypto’s pullback: CNBC Crypto World
World

Why XRP ETFs are seeing steady inflows despite crypto’s pullback: CNBC Crypto World

ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email On today’s episode of CNBC Crypto World, bitcoin falls as Wall Street rethinks some AI investments. Also, CF Benchmarks CEO Sui Chung discusses recent trends in crypto ETFs. Source

Read More
The chart that has Michael Burry worried about the stock market
World

The chart that has Michael Burry worried about the stock market

Michael Burry is warning that a shift in household wealth could leave the stock market vulnerable to a long and significant downturn. “The Big Short” investor pointed to a graphic produced by Wells Fargo showing that U.S. households now hold a larger share of their net worth in equities than in real estate — a […]

Read More
This biotech name is evolving into a major obesity play. How to trade it with options
World

This biotech name is evolving into a major obesity play. How to trade it with options

Amgen is entering a pivotal period the as it moves beyond its Enbrel franchise and repositions around obesity, rare disease and next-generation oncology. While Enbrel has entered a period of decline due to Medicare pricing reform, management has demonstrated credible execution in replacing that cash flow with a higher-quality pipeline. Early success from the Imdelltra […]

Read More